医学综述
醫學綜述
의학종술
MEDICAL RECAPITULATE
2015年
7期
1332-1334
,共3页
难治性精神分裂症%奥氮平%氟奋乃静%氨磺必利
難治性精神分裂癥%奧氮平%氟奮迺靜%氨磺必利
난치성정신분렬증%오담평%불강내정%안광필리
Refractory schizophrenia%Olanzapine%Fluphenazine%Amisulpride
目的：探讨氟奋乃静联合氨磺必利治疗难治性精神分裂症的临床疗效及安全性。方法将2009年11月至2012年11月新乡医学院第二附属医院收治的85例难治性精神分裂症者按照随机数字表法分为两组：奥氮平组（42例）口服奥氮平5～10 mg／d，每日2次；联合组（43例）口服氟奋乃静4～8 mg／d＋氨磺必利400～800 mg／d，每日2次。采用阳性和阴性症状量表（ PANSS）、临床总体印象量表（ CGI）、功能大体评定量表（ GAF）和不良反应量表（ TESS）评定两组患者的临床疗效和不良反应情况。结果奥氮平组的有效率为59.5％，联合组为72.1％，两组疗效比较差异有统计学意义（P＜0.05）；联合组PANSS总分、阳性症状分、阴性症状分、精神病理分及 CGI－SI总分均显著低于奥氮平组（P＜0.01），而联合组GAF分高于奥氮平组（P＜0.01）。联合组的不良反应发生率及复发率显著低于奥氮平组（48.8％比57.1％，20.9％比31.0％）（P＜0.05或P＜0.01）。结论氟奋乃静联合氨磺必利治疗难治性精神分裂症的临床疗效显著，不良反应少，依从性好。
目的：探討氟奮迺靜聯閤氨磺必利治療難治性精神分裂癥的臨床療效及安全性。方法將2009年11月至2012年11月新鄉醫學院第二附屬醫院收治的85例難治性精神分裂癥者按照隨機數字錶法分為兩組：奧氮平組（42例）口服奧氮平5～10 mg／d，每日2次；聯閤組（43例）口服氟奮迺靜4～8 mg／d＋氨磺必利400～800 mg／d，每日2次。採用暘性和陰性癥狀量錶（ PANSS）、臨床總體印象量錶（ CGI）、功能大體評定量錶（ GAF）和不良反應量錶（ TESS）評定兩組患者的臨床療效和不良反應情況。結果奧氮平組的有效率為59.5％，聯閤組為72.1％，兩組療效比較差異有統計學意義（P＜0.05）；聯閤組PANSS總分、暘性癥狀分、陰性癥狀分、精神病理分及 CGI－SI總分均顯著低于奧氮平組（P＜0.01），而聯閤組GAF分高于奧氮平組（P＜0.01）。聯閤組的不良反應髮生率及複髮率顯著低于奧氮平組（48.8％比57.1％，20.9％比31.0％）（P＜0.05或P＜0.01）。結論氟奮迺靜聯閤氨磺必利治療難治性精神分裂癥的臨床療效顯著，不良反應少，依從性好。
목적：탐토불강내정연합안광필리치료난치성정신분렬증적림상료효급안전성。방법장2009년11월지2012년11월신향의학원제이부속의원수치적85례난치성정신분렬증자안조수궤수자표법분위량조：오담평조（42례）구복오담평5～10 mg／d，매일2차；연합조（43례）구복불강내정4～8 mg／d＋안광필리400～800 mg／d，매일2차。채용양성화음성증상량표（ PANSS）、림상총체인상량표（ CGI）、공능대체평정량표（ GAF）화불량반응량표（ TESS）평정량조환자적림상료효화불량반응정황。결과오담평조적유효솔위59.5％，연합조위72.1％，량조료효비교차이유통계학의의（P＜0.05）；연합조PANSS총분、양성증상분、음성증상분、정신병리분급 CGI－SI총분균현저저우오담평조（P＜0.01），이연합조GAF분고우오담평조（P＜0.01）。연합조적불량반응발생솔급복발솔현저저우오담평조（48.8％비57.1％，20.9％비31.0％）（P＜0.05혹P＜0.01）。결론불강내정연합안광필리치료난치성정신분렬증적림상료효현저，불량반응소，의종성호。
Objective To evaluate the therapeutic efficacy and adverse effects of fluphenazine combined with amisulpride in treating refractory schizophrenia.Methods A total of 85 patients with refractory schizo-phrenia admitted in the Second Affiliated Hospital of Xinxiang Medical University from Nov .2009 to Nov. 2012 were randomly divided into combined treatment group(43 cases) and olanzapine group(42 cases) by the random number table method.Patients in olanzapine group orally took 5-10 mg/d of olanzapine,twice a day,while patients in combined treatment group orally took4-8 mg/d of fluphenazine combined with 400-800 mg/d of amisulpride,twice a day.Positive and negative syndrome scale(PANSS),clinical global impression (CGI),global assessment function(GAF) and treatment emergent symptoms scale(TESS) were used to evaluate the therapeutic efficacy and adverse effects.Results The marked effective rate of olanzapine group was 59.5%,that of the combined treatment group was 72.1%.There was statistically significant difference of the total effective rate between the two groups(P<0.05).Compare with the olanzapine group,scores of PANSS-G(general psychopathology scale),PANSS-P (positive scale),PANSS-T(total score),as well as the CGI-SI scores of the combined treatment group were all lower,while GAF score was significantly increased(P<0.01 ) .The incidence rate of adverse reaction and recurrence rate of the combined treatment group were significantly lower than those of the olanzapine group(48.8% vs 20.9%),(57.1% vs 31.0%) (P<0.05 or P<0.01).Conclusion Fluphenazine combined with amisulpride has good efficacy in treating refractory schizophrenia,with less side effects and good compliance.
